Advertisement covers The 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)

CROI 2012: New Integrase Inhibitor Dolutegravir Continues to Do Well

March 26, 2012

Study results show this new integrase inhibitor may be more advantageous over the current Isentress (raltegravir) and the experimental elvitegravir, including once daily dosing (Isentress is taken twice a day) and no need for a boosting drug (as with elvitegravir). Earlier study has shown that dolutegravir is effective against strains of HIV that are resistant to the other two integrase inhibitors.

This small study in 205 people who had never been on treatment compared three doses of dolutegravir to Sustiva. Average CD4 count was 324 and about 20% had viral loads above 100,000.

After 96 weeks, average CD4 count gains were similar between the dolutegravir arms (339) and Sustiva (301). Undetectable viral loads were seen at 88% on the 50mg dose, 78% on 25mg, 79% on 10mg and 72% on Sustiva. Fewer general side effects occurred on dolutegravir (11%) compared to Sustiva (24%). No resistance was seen in any of the participants.

Although these results come from the dose-ranging studies of dolutegravir, the drug is now in later-stage studies of treatment-experienced people and those going on treatment for the first time. It's possible that we could see this drug approved by the FDA in 2013, and perhaps combined into a full-regimen pill.

This article was provided by Project Inform. Visit Project Inform's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.